Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
The partial r2 and estimated effect sizes for each clinical-genetic marker pair tested are presented in Table 3 and Supplementary Table 3.Effects of genetics on baseline levels and on longitudinal changes of clinical markers.Clinical MarkeraGenetic FeaturebBaseline % Variation ExplainedcGenetic stratadDifference at BaselineeDifference in Longitudinal ΔfLDL-C, mg/dLLDL-C PGS11.1%Q1 −15.74 (−18.80, −12.59) −3.82 (−5.92, −1.72) Q2/Q3RefRefQ4 13.69 (10.16, 17.22) −0.91 (−3.00, 1.18)Total Cholesterol, mg/dLTotal Cholesterol PGS8.7%Q1 −13.82 (−17.42, −10.22) −4.32 (−6.77, −1.88) Q2/Q3RefRefQ4 15.79 (11.95, 19.64) −0.61 (−3.04, 1.81)HDL-C, mg/dLHDL-C PGS6.9%Q1 −6.02 (−7.75, −4.28) −0.58 (−1.47, 0.32)Q2/Q3RefRefQ4 6.67 (4.79, 8.55) 1.25 (0.38, 2.12) Triglycerides, mg/dLTriglycerides PGS3.9%Q1 −13.44 (−18.34, −8.55) −1.96 (−5.44, 1.52)Q2/Q3RefRefQ4 15.76 (9.62, 21.90) 5.14 (1.68, 8.60) Waist circumference (Females), inchesWaist circumference PGS (Females)3.2%Q1−0.98 (−2.00, 0.04)−0.37 (−0.80, 0.05)Q2/Q3RefRefQ4 1.98 (0.86, 3.10) −0.29 (−0.71, 0.13)Waist circumference (Males), inchesWaist circumference PGS (Males)1.8%Q1−0.47 (−1.45, 0.51)0.18 (−0.26, 0.62)Q2/Q3RefRefQ4 1.41 (0.34, 2.47) 0.04 (−0.39, 0.46)Body mass index (BMI Females), kg/m2BMI PGS (Females)2.7%Q1 −1.39 (−2.19, −0.58) 0.04 (−0.10, 0.19)Q2/Q3RefRefQ4 1.71 (0.84, 2.58) 0.09 (−0.05, 0.23)Body mass index (BMI Males), kg/m2BMI PGS (Males)1.7%Q1−0.22 (−0.90, 0.47)0.02 (−0.14, 0.17)Q2/Q3RefRefQ4 1.33 (0.54, 2.13) 0.09 (−0.06, 0.25)Homocysteine, μmol/LHomocysteine PGS0.7%LowRefRefModerate0.01 (−0.28, 0.30)−0.19 (−0.39, 0.00)High 0.73 (0.20, 1.26) −0.03 (−0.34, 0.28)Arachidonic acid, % by wtrs17453713.8%TTRefRefGT 0.9 (0.65, 1.14) 0.32 (0.12, 0.52) GG 1.83 (1.59, 2.08) 0.63 (0.41, 0.85) EPA, % by wtrs1745371.8%TTRefRefGT 0.11 (0.05, 0.17) 0.05 (−0.04, 0.15)GG 0.17 (0.11, 0.23) 0.07 (−0.02, 0.17)DPA, % by wtrs1745371.8%TTRefRefGT 0.05 (0.01, 0.09) 0.02 (−0.01, 0.05)GG 0.09 (0.05, 0.12) 0.01 (−0.02, 0.05)Vitamin D, ng/mLrs45881.5%GGRefRefGT −1.81 (−2.97, −0.64) 0.11 (−0.79, 1.00)TT −6.01 (−8.17, −3.86) −1.68 (−3.43, 0.06)hsCRP, mg/Lrs12050.5%TTRefRefCT0.55 (−0.04, 1.14)0.05 (−0.31, 0.41)CC 0.89 (0.30, 1.47) 0.21 (−0.15, 0.58)Systolic, mmHgrs6990.1%AARefRefAG−0.61 (−2.11, 0.88)0.12 (−0.91, 1.15)GG−0.85 (−2.79, 1.09)0.06 (−1.26, 1.38)Diastolic, mmHgrs6990.0%AARefRefAG−0.13 (−1.17, 0.91)−0.24 (−0.97, 0.49)GG0.24 (−1.16, 1.65)−0.75 (−1.68, 0.18)aClinical marker of interest followed by unit.bGenetic feature used to measure genetic predisposition for corresponding clinical marker; polygenic scores (PGS) or single nucleotide polymorphisms as indicated.c% variation explained of baseline levels of corresponding clinical marker by genetic feature.dStrata examined, defined by genetic feature; quartile (Q) or genotype as indicated.eEstimated difference in baseline levels of corresponding clinical marker compared to reference genetic strata.fEstimated difference in longitudinal change of corresponding clinical marker compared to reference genetic strata.Q1/2/3/4: quartile 1/2/3/4; Ref: reference genetic strata.Bolded values indicate p<0.05.See Supplementary Table 3 for p-values and adjusted p-values.
Source: Phenotypic Variation in Baseline Measures Explained by Genetic Markers. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
All research was conducted in accordance to regulations and guidelines for observational research in human subjects.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Genetic Predisposition Impacts Clinical Changes in a Lifestyle Coaching Program
Study design awaiting verification · Scientific Reports · 2019
Original publication title
Genetic Predisposition Impacts Clinical Changes in a Lifestyle Coaching Program
© The Author(s) 2019
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
What does the authors’ abstract report?
Both genetic and lifestyle factors contribute to an individual’s disease risk, suggesting a multi-omic approach is essential for personalized prevention. Studies have examined the effectiveness of lifestyle coaching on clinical outcomes, however, little is known about the impact of genetic predisposition on the response to lifestyle coaching. Here we report on the results of a real-world observational study in 2531 participants enrolled in a commercial “Scientific Wellness” program, which combines multi-omic data with personalized, telephonic lifestyle coaching. Specifically, we examined: 1) the impact of this program on 55 clinical markers and 2) the effect of genetic predisposition on these clinical changes.
We identified sustained improvements in clinical markers related to cardiometabolic risk, inflammation, nutrition, and anthropometrics. Notably, improvements in HbA1c were akin to those observed in landmark trials. Furthermore, genetic markers were associated with longitudinal changes in clinical markers. For example, individuals with genetic predisposition for higher LDL-C had a lesser decrease in LDL-C on average than those with genetic predisposition for average LDL-C. Overall, these results suggest that a program combining multi-omic data with lifestyle coaching produces clinically meaningful improvements, and that genetic predisposition impacts clinical responses to lifestyle change.
Authors’ abstract
Both genetic and lifestyle factors contribute to an individual’s disease risk, suggesting a multi-omic approach is essential for personalized prevention. Studies have examined the effectiveness of lifestyle coaching on clinical outcomes, however, little is known about the impact of genetic predisposition on the response to lifestyle coaching. Here we report on the results of a real-world observational study in 2531 participants enrolled in a commercial “Scientific Wellness” program, which combines multi-omic data with personalized, telephonic lifestyle coaching. Specifically, we examined: 1) the impact of this program on 55 clinical markers and 2) the effect of genetic predisposition on these clinical changes.
We identified sustained improvements in clinical markers related to cardiometabolic risk, inflammation, nutrition, and anthropometrics. Notably, improvements in HbA1c were akin to those observed in landmark trials. Furthermore, genetic markers were associated with longitudinal changes in clinical markers. For example, individuals with genetic predisposition for higher LDL-C had a lesser decrease in LDL-C on average than those with genetic predisposition for average LDL-C. Overall, these results suggest that a program combining multi-omic data with lifestyle coaching produces clinically meaningful improvements, and that genetic predisposition impacts clinical responses to lifestyle change.
Publication and source details
Original title: Genetic Predisposition Impacts Clinical Changes in a Lifestyle Coaching Program
Niha Zubair; Matthew P. Conomos; Leroy Hood; Gilbert S. Omenn; Nathan D. Price; Bonnie J. Spring; Andrew T. Magis; Jennifer C. Lovejoy
Scientific Reports · 2019
© The Author(s) 2019https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-12T18:36:20.843320+00:00
DOI: 10.1038/s41598-019-43058-0 · PMC6497671